Dana Farber Researcher Looks to RNAi to Help Find New Roles of mTOR, Rapamycin | GenomeWeb

RNAi has proven to be so easy to use that many researchers who weren’t even aware of the gene-silencing technology until recently are taking advantage of it. Among them is Sharon Chang, a surgical resident at Dana-Farber Cancer Institute, who is using RNAi to uncover possible new roles for mammalian target of rapamycin, or mTOR, a kinase associated with cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.